- Home
- TIXT vs PHVS Comparison
TIXT vs PHVS Comparison
Compare TIXT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- PHVS
- Stock Information
- Founded
- TIXT 2005
- PHVS 2015
- Country
- TIXT Canada
- PHVS Switzerland
- Employees
- TIXT N/A
- PHVS N/A
- Industry
- TIXT EDP Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- TIXT Technology
- PHVS Health Care
- Exchange
- TIXT Nasdaq
- PHVS Nasdaq
- Market Cap
- TIXT 812.7M
- PHVS 980.9M
- IPO Year
- TIXT 2021
- PHVS 2021
- Fundamental
- Price
- TIXT $3.76
- PHVS $22.32
- Analyst Decision
- TIXT Hold
- PHVS Buy
- Analyst Count
- TIXT 9
- PHVS 6
- Target Price
- TIXT $4.17
- PHVS $37.17
- AVG Volume (30 Days)
- TIXT 1.3M
- PHVS 33.8K
- Earning Date
- TIXT 08-01-2025
- PHVS 08-13-2025
- Dividend Yield
- TIXT N/A
- PHVS N/A
- EPS Growth
- TIXT N/A
- PHVS N/A
- EPS
- TIXT N/A
- PHVS N/A
- Revenue
- TIXT $2,671,000,000.00
- PHVS N/A
- Revenue This Year
- TIXT $3.61
- PHVS N/A
- Revenue Next Year
- TIXT $3.59
- PHVS N/A
- P/E Ratio
- TIXT N/A
- PHVS N/A
- Revenue Growth
- TIXT N/A
- PHVS N/A
- 52 Week Low
- TIXT $2.13
- PHVS $11.51
- 52 Week High
- TIXT $6.86
- PHVS $25.76
- Technical
- Relative Strength Index (RSI)
- TIXT 66.56
- PHVS 73.31
- Support Level
- TIXT $3.55
- PHVS $17.63
- Resistance Level
- TIXT $3.92
- PHVS $19.00
- Average True Range (ATR)
- TIXT 0.10
- PHVS 1.20
- MACD
- TIXT -0.01
- PHVS 0.35
- Stochastic Oscillator
- TIXT 60.71
- PHVS 92.15
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.